Atossa Therapeutics, Inc.
ATOS
$0.89
$0.011.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.78% | -1.14% | -3.84% | -5.13% | -5.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.90% | -10.25% | -11.97% | -3.31% | -2.12% |
| Operating Income | 1.90% | 10.25% | 11.97% | 3.31% | 2.12% |
| Income Before Tax | -10.84% | 11.27% | 15.25% | 9.79% | 18.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.84% | 11.27% | 15.25% | 9.79% | 18.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.84% | 11.27% | 15.25% | 9.79% | 18.04% |
| EBIT | 1.90% | 10.25% | 11.97% | 3.31% | 2.12% |
| EBITDA | 1.87% | 10.23% | 11.96% | 3.36% | 2.17% |
| EPS Basic | -8.91% | 11.95% | 15.09% | 9.11% | 17.34% |
| Normalized Basic EPS | -2.33% | 8.59% | 12.13% | 5.43% | 8.70% |
| EPS Diluted | -8.91% | 11.95% | 15.09% | 9.11% | 17.34% |
| Normalized Diluted EPS | -2.33% | 8.59% | 12.13% | 5.43% | 8.70% |
| Average Basic Shares Outstanding | 1.71% | 0.85% | -0.18% | -0.70% | -0.86% |
| Average Diluted Shares Outstanding | 1.71% | 0.85% | -0.18% | -0.70% | -0.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |